Under the terms of the agreement, Vermillion is granted exclusive rights to the biomarker panel, and will undertake the development and commercialization of a PAD blood test, which utilizes the multi-marker panel to stratify an individual’s risk for developing the disease.
In collaboration with Stanford, Vermillion has completed a 540-patient clinical study evaluating the ability of the biomarker panel to classify individuals into high and low risk groups for PAD. Additionally, Vermillion is establishing a clinical steering committee to guide and provide advice on a clinical trial to support registration of the PAD test with the FDA.